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Abstract
Methamphetamine (METH) is an addictive and neurotoxic psychostimulant widely abused in the USA and throughout the
world. When administered in large doses, METH can cause depletion of striatal dopamine terminals, with preservation of
midbrain dopaminergic neurons. Because alterations in the expression of transcription factors that regulate the
development of dopaminergic neurons might be involved in protecting these neurons after toxic insults, we tested the
possibility that their expression might be affected by toxic doses of METH in the adult brain. Male Sprague-Dawley rats
pretreated with saline or increasing doses of METH were challenged with toxic doses of the drug and euthanized two weeks
later. Animals that received toxic METH challenges showed decreases in dopamine levels and reductions in tyrosine
hydroxylase protein concentration in the striatum. METH pretreatment protected against loss of striatal dopamine and
tyrosine hydroxylase. In contrast, METH challenges caused decreases in dopamine transporters in both saline- and METH-
pretreated animals. Interestingly, METH challenges elicited increases in dopamine transporter mRNA levels in the midbrain
in the presence but not in the absence of METH pretreatment. Moreover, toxic METH doses caused decreases in the
expression of the dopamine developmental factors, Shh, Lmx1b, and Nurr1, but not in the levels of Otx2 and Pitx3, in saline-
pretreated rats. METH pretreatment followed by METH challenges also decreased Nurr1 but increased Otx2 and Pitx3
expression in the midbrain. These findings suggest that, in adult animals, toxic doses of METH can differentially influence
the expression of transcription factors involved in the developmental regulation of dopamine neurons. The combined
increases in Otx2 and Pitx3 expression after METH preconditioning might represent, in part, some of the mechanisms that
served to protect against METH-induced striatal dopamine depletion observed after METH preconditioning.
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Introduction
Methamphetamine (METH) is a psychostimulant that is abused
throughout the world. Acute administration of the drug causes
behavioral changes that are secondary to activation of dopaminergic
systemslocatedinvariousbrainregions[1].ChronicabuseofMETH
causes adverse neuropsychiatric effects which include addiction,
psychosis and cognitive impairments (reviewed in [2]) and, possibly,
Parkinsonism [3]. Some of the cognitive abnormalities are thought to
be related to METH-induced neurodegenerative changes in the
brains of human addicts [4]. Of significant concern are the findings
from imaging and postmortem studies describing decreases in the
density of striatal dopamine transporters (DAT), reductions in
tyrosine hydroxylase (TH) levels as well as decreases in the
concentrations of dopamine (DA) in the brains of chronic METH
abusers [5,6]. In fact, these abnormalities might reflect damage to DA
neurons and the possibility that dysfunctional DA neurons could lead
to the appearance of neurological syndromes over time [7,8].
In preclinical studies, injections of moderate-to-large doses of
METH cause depletion of DA as well as loss of DAT and TH in
the striatum of rodents and non-human primates [8]. These
changes occur without any clear evidence of DA neuronal death in
the midbrain (reviewed in [7,8]). On the other hand, injections of
increasing but nontoxic METH doses provide protection against
subsequent challenges with larger toxic doses of the drug [9–12].
We recently termed this process, METH preconditioning [9],
because of its similarities to other neuroprotective preconditioning
paradigms [13]. Although it has become clear that METH-
induced depletion of DA and decreases in DAT and TH
expression in the striatum are dependent on toxic processes such
as the production of free radicals, generation of DA quinones,
glutamate-mediated formation of nitric oxide, and temperature
dysregulation (reviewed in [8]), much remains to be done to clarify
the mechanisms responsible for the lack of cell death of midbrain
DA neurons and to explain the progressive recovery of DA levels
in METH-treated rodents [14,15]. We thought that repeated
injections of METH might generate a tolerant state that imbues
midbrain DA cells with a certain degree of resistance against the
axonal retrograde degeneration that is observed after intrastriatal
injections of 6-hydroxydopamine (6-OHDA) [16,17] since METH
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thought that the development of this tolerant state, that guards
against midbrain neuronal death, might be secondary to METH-
induced recapitulation of molecular events that are engaged in the
generation, promotion, and protection of DA neurons during
developmental stages in utero [19,20]. Specifically, the develop-
ment of mesostriatal dopaminergic pathways is coordinated by the
interactions of diverse differentiating and maintenance signals that
are being dissected by various research groups [20,21]. These
include transcription factors OTX2, WNT1, SHH, FGF8, LMX
and MSX that are involved in regulating the early development of
DA neurons [22–26]. Other transcription factors of interest are
NURR1 and PITX3 which participate in the induction and
maintenance of DA neurons and cooperate to promote their
maturation [27–30]. Because some of these transcription factors
continue to be expressed in the adult CNS, we reasoned that they
might also mediate the preservation of the dopaminergic
phenotype and survival of DA neurons in the adult brain. Herein,
we report, for the first time, that challenges with toxic doses of
METH caused significant changes in the expression of transcrip-
tion factors that are involved in the development of midbrain
dopaminergic neurons. This differential regulation might be
important to the maintenance of midbrain DA neurons in the
presence of METH-induced degeneration of striatal DA terminals.
Materials and Methods
Animals
Male Sprague-Dawley rats (Charles River Laboratories, Ra-
leigh, NC) weighing approximately 350–400 g were habituated for
one week prior to drug treatment. Animals were housed in
polyethylene cages containing hardwood bedding in a tempera-
ture-controlled room with a 12 hour light:dark cycle and free
access to food and water. All animal procedures were performed
according to the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Animal Care
and Use Committee of the National Institute on Drug Abuse,
Intramural Research Program. The research was conducted under
Animal Study Protocol #09-CNRB-25.
Drug Treatment and Tissue Collection
After habituation, rats were injected with saline or with
progressively higher doses of d,l-METH hydrochloride for two
weeks as described in Table S1. The saline-pretreated group was
further divided into three subgroups. Rats from the first subgroup
were given saline and challenged twice with saline during the third
week of the experiment (SSS). Rats form the second subgroup
were challenged with METH (5 mg/kg66, given 1 hour apart)
(SSM). The third subgroup received two challenges of the same
doses of METH within three days (SMM). Animals pretreated
with METH were also challenged with METH (MMM). Clinical
studies have indicated that most human METH addicts initially
use low doses of the drug, taken at variable intervals; this is
followed by progressive dose increases and subsequent escalation
to repeated binges, with consumption of about 20 g of METH per
week separated by variable lengths of abstinence [31–33].
Therefore, to better approximate METH abuse patterns reported
in humans, we administered METH to rats according to a
regimen of escalating METH doses followed by multiple drug
binges. Models similar to this one have been previously used by
several groups of investigators who study METH toxicity [9–
11,34–37].
Rats were weighed three times per week during the pretreat-
ment period and both challenge days to ensure proper dosing.
Tympanic temperatures were taken 30 minutes prior to the first
injection and 30 minutes after every other injection on the second
challenge day. The animals were euthanized 14 days following the
METH challenge by decapitation. Their brains were then quickly
removed, dorsal striata and midbrain regions were dissected over
ice, snap frozen on dry ice, and stored at 280uC until used in
biochemical experiments.
HPLC
For monoamine analysis, the dorsal striata of 5–8 mice per
group were homogenized in 0.01 M HClO4 and centrifuged at
140006 g for 15 min. DA, 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA) levels were analyzed in
the striatal extracts using HPLC with electrochemical detector as
described previously [38] and expressed as pg/mg of tissue weight.
qRT-PCR
Total RNA extracted from a midbrain region that encompasses
the ventral tegmental area and substantia nigra of the rat was used
to analyze the expression of genes of interest by qRT-PCR as
previously described [34,39,40]. In brief, unpooled total RNA
obtained from 5–7 rats per group was reverse-transcribed with
oligo dT primers and Advantage RT for PCR kit (Clontech, Palo
Alto, CA). PCR experiments were performed using LightCycler
FastStart DNA Master SYBR Green I kit (Roche, Indianapolis,
IN) according to manufacturer’s protocol. Sequences for gene-
specific primers corresponding to PCR targets were obtained using
LightCycler Probe Design software (Roche). The primers were
synthesized and HPLC-purified at the Synthesis and Sequencing
Facility of Johns Hopkins University (Baltimore, MD). PCR values
were normalized using 18S rRNA and quantified. The results are
reported as fold changes calculated as the ratios of normalized
gene expression data of each group in comparison to the SSS
group.
Western Blot analysis
Western blot analyses were performed as previously published
[41,42]. In brief, dorsal striatal and midbrain samples were washed
with ice-cold 0.1 M PBS, homogenized in lysis buffer (0.01 M
Tris-HCl, pH 7.6, 0.1 M NaCl, 0.001 M EDTA, 100 mg/ml
PMSF and 1 mg/ml aprotinin) and then centrifuged at 150006g
for 30 min. Protein concentrations were determined with BioRad
Dc Protein assay (BioRad, Temecula, CA). 20 mg of total protein
were electrophoresed on 10% SDS-polyacrylamide gels and then
transferred to Hybond-P
TM membrane (GE Healthcare, Piscat-
away, NJ). The membranes were blocked and then immunola-
beled with antibodies against DAT (1:1000), TH (1:10000), Pitx-3
(1:1000) (all from Millipore, Billerica, MA) and Nurr1 (1:1000;
ThermoFisher Scientific, Waltham, MA) at 4uC overnight.
Immune complexes were detected with HRP-labeled second
antibody and ECL+ chemiluminescence reagents (GE Health-
care). To confirm equal protein loading, blots were stripped and
reprobed with anti-a-tubulin antibody (1:3000; Sigma, St. Louis,
MO) for 2 hours at room temperature. Signal intensity was
measured using densitometric analysis (Image Station 4000 MM
Pro; Carestream Health, Inc., Rochester, NY) and quantified
using Carestream Molecular Imaging Software (version 5.0.2.30,
Carestream Health, Inc.).
Statistical Analyses
All data are presented as means 6 SEM. Statistical analysis of
the experimental data on body temperature and weights was
performed using two-way ANOVA for repeated measures
METH and Transcription Factors in the Midbrain
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test) to identify differences between the groups or sessions,
respectively (SigmaStat software, http://www.systat.com). Statis-
tical analysis of HPLC, qRT-PCR and Western blot data was
performed using one-way ANOVA for repeated measures
followed by Fisher’s protected least significant difference (PLSD)
(StatView 4.02, SAS Institute, Cary, NC). The null hypothesis was
rejected at p,0.05.
Results
METH-induced changes in body weights and
temperature
The effects of METH pretreatment and challenges on body
weights in rats are shown in Figure 1. There were no significant
differences in body weights between saline- and METH-pretreated
groups before initiating the pretreatments (Fig. 1). Rats in both
groups showed significant increases in their body weights at the
end of the pretreatment period. However, METH-pretreated rats
gained significantly less weight than saline-pretreated group,
+6.3% vs +10.6%, respectively (Fig. 1). There were no significant
differences in body weights between the four groups of rats prior to
challenges on Day 15 (Fig. 1). The SSS group showed increases in
their body weights at the end of challenges. The single METH
challenge (SSM group) did not induce any significant changes in
body weights during the post-injection week. In contrast, the two
METH challenges caused decreases in rat body weights
independent of the type of pretreatment (28.4% for SMM group
and 27.5% for MMM group) (Fig. 1). Our findings of the weight
loss in rats challenged with METH are consistent with the
observations of Davidson [43] who reported decreased body
weights in rats treated with METH via mini-pumps. These data
Figure 1. Methamphetamine administration causes decreases in body weights in the rat. (A) Rats pretreated with saline and METH
showed increases in their body weights on Days 8, 10 and 12 in comparison to Day 1, with the METH group gaining significantly lower weights by
Day 12. (B) On day 15, The saline-pretreated group was then divided into 3 groups that received saline challenges (SSS) or a single (SSM) or two METH
challenges (SMM). The SSS group continued to gain weight after two saline challenges given on Day 22. However, rats challenged once with METH
(SSM group) did not show significant changes in their body weights. In contrast, animals challenged twice with METH (SMM and MMM groups)
showed reduction of their body weights in comparison to SSS and SSM groups on Days 19 and 22. The arrows indicate the day of saline or METH
injections. Values are expressed as means 6 SEM. (N=6–32 animals per group). Key to statistics:
a p,0.05 in comparison to Day 1;
b p,0.05 in
comparison to saline-pretreated group;
c p,0.05 in comparison to Day 15;
d p,0.05 in comparison to SSS group;
e p,0.05 in comparison to SSM
group.
doi:10.1371/journal.pone.0019179.g001
Figure 2. METH treatment induced increases in tympanic
temperatures in rats. Temperatures were measured in all treatment
groups after injections of either saline or METH or saline challenges
(shown by arrows). Rats from the first group were given saline and
challenged twice with saline during the third week of the experiment
(SSS). Rats from the second group were challenged with METH (5 mg/
kg66, given 1 hour apart) (SSM). The third group received two
challenges of the same doses of METH within three days (SMM).
Animals from the fourth group pretreated with METH were also
challenged with the drug (MMM). Values are expressed as means 6
SEM. N=6–10 animals per group. Key to statistics:
a p,0.001 versus SSS
group;
b p,0.05 versus SSM and MMM groups.
doi:10.1371/journal.pone.0019179.g002
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rats that self-administered METH [41]. In addition, our findings
are in agreement with significant anorexia and weight loss
reported in human METH abusers [33,44,45].
Figure 2 shows the changes in rat body temperatures caused by
the second METH challenges. There were no significant
differences in body temperatures between the groups before
METH injections. After the first injection, all METH-treated
animals experienced significantly higher body temperatures than
rats treated with saline. These increases in body temperature
persisted throughout the time of observation. Interestingly, rats
pretreated with saline and challenged with METH showed
significantly higher core body temperature in response to the
second drug challenge (SMM group) in comparison to SSM and
MMM groups (Fig. 2).
METH pretreatment protects against METH-induced
depletion of striatal monoamines
Table 1 shows the effects of challenges with toxic doses of
METH on DA, DOPAC, and HVA levels in the striatum at 14
days after treatment. In agreement with previous studies [8],
repeated injections of toxic doses of METH during a single day
caused substantial depletion of DA and its metabolites in saline-
pretreated animals. An identical challenge given three days later
did not cause any further reduction in DA nor its metabolites. As
previously reported by us and others [9,10,12], METH pretreat-
ment provided protection against DA and DOPAC depletion in
the striatum.
Effects of METH on striatal TH and DAT protein levels
The effects of METH on TH and DAT protein levels in the rat
striatum are presented in Fig. 3. A single-day toxic METH
challenge caused significant decreases in TH protein expression in
rats euthanized two weeks after drug injections (Fig. 3A). An
additional METH challenge, given three days later, did not
potentiate the toxicity of the drug. Similar to its effects on DA
levels, METH preconditioning caused protection against decreases
in TH protein expression in the striatum.
METH-induced changes on striatal DAT expression are shown
in Fig. 3B. The single and double METH challenges caused
similar decreases in striatal DAT expression in the animals
pretreated with saline. METH challenges also decreased DAT
Table 1. Effects of METH preconditioning and challenges on the levels of DA, DOPAC and HVA in the rat striatum.
Group DA (pg/mg of tissue) DOPAC (pg/mg of tissue) HVA (pg/mg of tissue)










Values represent means 6 SEM (N=5–8 per group).
ap,0.01 in comparison to SSS group.
bp,0.05 in comparison to SSM and SMM groups.
doi:10.1371/journal.pone.0019179.t001
Figure 3. METH challenges caused decreases in TH and DAT protein levels in the striatum. METH preconditioning resulted in complete
protection against decreases in TH protein levels (A). In contrast, METH preconditioning was only partially protective against METH toxic effects on
DAT protein expression (B). The groups are as described in the legend to Fig. 2. The quantification data represent fold changes (means 6 SEM) in
comparison to the saline-pretreated group challenged with saline (SSS group). N=3–6 animals per group. Keys to statistics: **, *** p,0.01, 0.001,
respectively, in comparison to the SSS group; # p,0.05; in comparison to the SSM group (panels A and B).
doi:10.1371/journal.pone.0019179.g003
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the latter group were higher than those measured in the saline-
pretreated METH-challenged group (SSM).
Effects of METH on midbrain TH and DAT mRNA and
protein levels
Figure 4 shows Th and Dat mRNA levels in the midbrain of the
animals pretreated with saline or METH before the drug
challenges. Similar to the results of a previous report on the
effects of amphetamine on Th mRNA [46], a single METH
challenge associated with decreased striatal TH protein caused no
changes in midbrain Th mRNA levels (Fig. 4A). However, two
METH challenges caused increases in Th mRNA levels in the
midbrain of rats pretreated with saline. METH pretreatment
followed by METH challenges was also associated with normal
levels of Th mRNA expression (Fig. 4A). Neither a single nor two
METH challenges resulted in significant changes in Dat mRNA
levels in rats pretreated with saline. Unexpectedly, there were
marked METH-induced increases in Dat mRNA expression in the
METH preconditioned animals (Fig. 4B). The effects of METH
on TH and DAT protein levels in the midbrain are shown in
Fig. 4C, D. The drug did not cause any significant changes in their
expression in any of the METH-treated groups.
Effects of METH on midbrain mRNA levels of
differentiating factors of DA neurons
Effects of METH on midbrain Otx2, Wnt, Shh, and Fgf8
mRNA levels. The expression of TH and DAT is regulated
during development by a number of transcription and trophic
factors including OTX2, WNT1, SHH and FGF8 which are
involved in early differentiation of midbrain DA neurons [22,24–
26,47]. Thus, we reasoned that toxic doses of METH might have
differential effects on the expression of these factors in the
absence or presence of drug preconditioning. Figure 5A shows
that METH challenges caused increases in Otx2 expression in the
METH- but not in the saline-pretreated rats. A single METH
challenge decreased Wnt1 mRNA levels but these effects did not
reach significance. In contrast, the animals that received two
METH challenges (SMM and MMM groups) experienced
significant reductions in Wnt1 expression regardless of
pretreatment (Fig. 5B). The single drug challenge also caused
non-significant decreases in Shh mRNA levels whereas the two
challenges led to significant decreases in the saline-pretreated
group (Fig. 5C). In contrast, Shh mRNA levels were normal in
METH-pretreated group after the drug challenges (Fig. 5C).
There were no significant changes in Fgf8 expression in any of the
METH-treated groups (Fig. 5D).
Figure 4. Effect of METH treatment on TH and DAT mRNA and protein levels in the midbrain. METH injections caused increases in TH
mRNA only in the saline-pretreated group challenged twice with toxic doses of the drug (A). METH toxic challenges induced increases in DAT mRNA
only in METH-pretreated rats (B). Total RNA was obtained from 5–6 animals per group, the mRNA expression was measured individually and
normalized to 18S rRNA levels. The METH challenges caused no significant changes in the expression of TH (C) and DAT (D) protein levels. The values
represent means 6 SEM in comparison to the saline-pretreated group challenged with saline (SSS group). N=3–5 animals per group. Keys to
statistics: *, **, *** p,0.05, 0.01, 0.001, respectively, in comparison to the SSS group; #, ##, ### p,0.05, 0.01, 0.001, respectively, in comparison to
the SSM group; !, !!, !!! p,0.05, 0.01, 0.001 respectively, in comparison to the SMM group.
doi:10.1371/journal.pone.0019179.g004
METH and Transcription Factors in the Midbrain
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families of transcription factors. Other factors that
participate in intermediate steps in the differentiation of DA
neurons during development include LMX1A, LMX1B, MSX1,
and MSX2 [48,49]. Figure 6 shows the effects of METH on their
expression. Lmx1a mRNA levels were decreased only in the group
challenged once with METH after saline pretreatment (Fig. 6A).
There also comparable decreases in Lmx1b expression in all drug-
treated groups regardless of pretreatment (Fig. 6B). Interestingly,
the two METH challenges caused increases in Msx1 expression in
the saline-pretreated group (Fig. 6C). In contrast, the single
METH challenge led to decreases in Msx2 expression (Fig. 6D) in
the saline-pretreated rats whereas other groups were not affected.
Effects of METH on midbrain Nurr1 and Pitx3 mRNA and
protein levels in the midbrain. We measured the expression
of NURR1 and PITX3 because they participate the molecular
regulation of TH and DAT levels during both developmental
stages and in adult life [50]. Figure 7 presents the effects of METH
on their expression in the midbrain. Unexpectedly, METH caused
significant and similar decreases in Nurr1 mRNA levels in the
presence and absence of METH pretreatment (Fig. 7A). In
contrast, there were METH challenge-induced increases in Pitx3
expression only in the METH-preconditioned rats (Fig. 7B).
Similar to the effects of METH on Nurr1 mRNA, there were
decreases in midbrain NURR1 protein levels in all the groups
(Fig. 7C). Moreover, the decreases observed in the METH-
pretreated group were of greater magnitude than those found in
the other two groups. METH challenges caused increases in
PITX3 protein levels in the midbrain in both groups (SMM and
MMM) that received two drug challenges irrespective of
pretreatment (Fig. 7D).
Discussion
Dopaminergic neurons of the ventral midbrain, which includes
ventral tegmental area (VTA) and substantia nigra pars compacta
(SNpc), play important roles in the control of motor and
psychomotor behaviors [1]. Functional and structural pathologies
in these systems form the substrates for Parkinson’s disease and
addictive disorders [51,52]. In the present study as in other
investigations [8], repeated injections of large doses of METH,
given within short time intervals, caused decreases in DA, TH, and
DAT in the rat striatum. We also showed that a second challenge
with METH did not elicit any further decreases in DA markers.
The lack of further reductions after the second METH challenge is
probably related to the fact that decreases in DAT binding are
measurable within 24 hours after injections of toxic doses of
METH [8] and to the findings that DAT is an important
determinant of METH toxicity [53]. In contrast, chronic
intermittent injections of non-toxic METH doses provided almost
complete protection against striatal DA depletion and against
decreases in TH protein levels induced by toxic METH
Figure 5. Effect of METH administration on Otx2, Wnt1, Shh and Fgf8 mRNA expression in the midbrain. There were increases in Otx2
mRNA expression only in the METH-preteated group challenged twice with toxic doses of the drug (A). Animals challenged twice with METH showed
significant decreases in Wnt1 expression (B). There were significant decreases in Shh expression only in saline-pretreated rats challenged twice with
METH (C). METH caused no changes in Fgf8 expression in any of the groups (D). Data were obtained by qRT-PCR using total RNA obtained from 5–6
animals per group. The values represent means 6 SEM in comparison to the saline-pretreated challenged with saline group (SSS). N=5–6 animals per
group. Keys to statistics are as described in Fig. 4.
doi:10.1371/journal.pone.0019179.g005
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allowed only partial protection against reductions in striatal DAT
protein levels even though Dat mRNA expression was robustly
increased in the midbrain. These observations suggest that
following drug-induced increased synthesis of DAT, the protein
might be rapidly degraded by METH-triggered pathways
including oxygen-based free radicals [8,18]. Alternatively, the
translation of mRNA into DAT protein or its transport towards
striatal DA terminals might be negatively impacted by the METH
injections. It is also important to note that, because all animals
independent of pretreatment showed significant hyperthermia
after the second METH challenge, it is unlikely that the protection
caused by METH preconditioning is dependent on changes in
temperature regulation.
The substantial loss of DA markers observed in the present
study following injections of toxic METH doses is consistent with
the observations of other investigators who used similar doses of
the drug [9–11,54–56], see [8] for review. The differential
protection of METH pretreatment against the toxic effects of
the drug, preventing the decreases in striatal DA and TH but not
the reductions in DAT were unexpected and points to a
dissociation of METH effects on these striatal markers. This idea
is consistent with recent papers that have documented differential
effects of METH administration on DA and DAT in striata of
rodents. For example, Xi et al. [57] reported that a single injection
of a moderately large dose of METH (20 mg/kg) caused marked
decreases in striatal DA levels measured one month after the
injection without affecting DAT binding. In contrast, Schwendt et
al. [58] found that extended METH self-administration was
associated with decreased DAT levels without affecting DA and
TH levels in the striatum. The latter findings are almost identical
to our observations in the METH-preconditioned rats challenged
with toxic doses of the drug. Yet, another study had reported
increases in TH mRNA and protein levels in the midbrain at 1
day, but not at 30 days, after cessation of METH self-
administration in rats [59]. In contrast, there were no effects of
METH on TH protein levels in striatal dopaminergic terminals.
Importantly, METH self-administration had no significant effects
on Dat mRNA levels in the midbrain [59]. Our findings are also
consistent with the observations in adult weaver mutant mice that
exhibit loss of DA neurons in the nigrostriatal dopaminergic
pathway [60]. Specifically, expression of Dat mRNA in remaining
SNpc dopaminergic neurons was decreased whereas the level of
Th mRNA was not affected in these animals [60]. Most
importantly, however, these observations indicate that the various
dopaminergic markers cannot be used interchangeably to study
METH toxicity in the rodent striatum.
The differential METH-induced changes in TH, DAT and DA
levels could also be secondary, in part, to perturbations in
transcription factors that influence the expression of these DA
Figure 6. METH treatment induced different changes in Lmx and Msx gene expression in midbrain. METH injections caused significant
decreases in Lmx1a expression only in the SSM group (A) but resulted in reductions in Lmx1b mRNA levels in all groups independent of pretreatment
(B). There were increases in Msx1 expression only in the saline-pretreated group challenged twice with METH (C). In contrast, METH caused decreases
in Msx2 expression in the SSM group (D). The values represent means 6 SEM in comparison to the saline-pretreated challenged with saline group
(SSS). N=5–6 animals per group. Keys to statistics are as described in Fig. 4.
doi:10.1371/journal.pone.0019179.g006
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SHH are involved in regulating the early development of DA
neurons [22,24–26,61]. Thus, it was of interest that the METH
challenges caused substantial increases in Otx2 mRNA only in the
animals pre-exposed to lower doses of METH. These observations
suggest that treatment with low non-toxic doses of the drug might
have altered the transcription of Otx2 to such an extent that
challenges with large METH doses were able to increase Otx2
mRNA levels in midbrain DA neurons in METH-preconditioned
rats but not in saline-pretreated animals. In contrast to Otx2
mRNA expression which was not affected by METH in saline-
pretreated animals, Shh transcript levels were markedly reduced in
these rats. SHH is thought to be responsible for ventral fate
determination during development [62], being important in the
formation, size, and shape of the ventral midbrain [22,61].
Conditional inactivation of Shh after 8 days, but not after 11 days,
of gestation causes loss of DA populations [63]. SHH also plays an
important role in the formation of DA axonal projections to rostral
brain regions including striatum [64]. Thus, the decreased
expression of the Shh transcript after METH challenges in the
two saline-pretreated groups, which show decreased dopaminergic
markers, in contrast to normal Shh mRNA levels in the METH-
preconditioned rats that exhibit normal levels of DA and TH
protein, suggest that SHH may play a partial role in maintaining
DA homeostasis in the striatum of METH pretreated rats.
Although much remains to be done to elucidate the role of
SHH by itself or in combination with OTX2 expression in
maintaining DA neurons in the adult brain, it is unlikely that
either one of them is involved in the METH-induced changes in
DAT expression since the drug caused significant decreases in
DAT expression in both saline- and METH-pretreated rats, albeit
to a lesser extent in the latter than in the former group.
Unexpectedly, we found that METH challenges caused
decreases in Nurr1 mRNA and protein levels in both saline- and
METH-pretreated rats. NURR1 is a member of the nuclear
receptor superfamily of transcription factors [65] and is very
important for the induction and maintenance of DA neurons
[28,29,66,67]. The expression of Nurr1 in the adult brain suggests
that it might play additional roles in the nervous system [68],
including maintenance of midbrain DA neurons [28]. Therefore,
the decreases in Nurr1 mRNA and protein levels in midbrain after
METH challenges both in saline- or METH-pretreated animals
are disconcerting because they might render DA neurons more
vulnerable to cell death. However, preclinical toxic doses of
METH or amphetamine that cause decreases in TH, DAT, and
DA levels in the striatum are not associated with DA cell loss in
SNpc ([69,70], reviewed in [8]). This lack of METH-induced
death of DA neurons might be related to the fact that toxic METH
challenges failed to cause perturbations in Pitx3 expression in
saline-pretreated animals while increasing Pitx3 expression in
Figure 7. METH caused differential changes in Nurr1 and Pitx3 mRNA and protein levels in the midbrain. METH injections resulted in
significant decreases in Nurr1 expression in all the groups (A). In contrast, METH challenges caused significant increases in Pitx3 mRNA expression
only in the METH-preconditioned rats (B). Consistent with the mRNA data, toxic METH challenges caused decreases in Nurr1 protein levels in all the
groups (C). In contrast, Pitx3 protein levels were increased by METH (D). The values represent means 6 SEM in comparison to the saline-pretreated
challenged with saline group (SSS). N=3–6 animals per group. Keys to statistics are as described in the legend to Fig. 4.
doi:10.1371/journal.pone.0019179.g007
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development of midbrain DA neurons is supported by findings
that both NURR1 and PITX3 can cooperate to promote the
maturation of DA neurons [29] and by observations showing the
loss of dopaminergic neurons in the midbrain of Pitx3-deficient
aphakia mice [71]. Because NURR1 and PITX3 bind to upstream
regulatory sequences in Th and Dat [27,29,30,72], the partial loss
of NURR1, without decreases in PITX3 expression, might be
enough to cause decreases in striatal TH protein levels but not
sufficient to induce retrograde degeneration of midbrain DA
neurons. This idea is consistent with the protection against
METH-induced decreases in TH expression and DA depletion in
the striatum of the METH-preconditioned group which shows
increased PITX3 expression in the midbrain.
In summary, we report that toxic doses of METH influence the
expression of DA differentiating factors in the absence and
presence of drug pretreatment, suggesting that repeated METH
injections might trigger substantial adaptive changes in transcrip-
tional responses in the adult mesostriatal dopaminergic system.
This is consistent with a notion that the amphetamines can
recapitulate developmental processes in the brain [73] since
amphetamine conditioned place preference is associated with
enrichment of transcription factors that regulate brain develop-
ment in the zebrafish [74]. Our observations also point to complex
regulatory networks involved in the control of DAT and TH
expression in the adult brain exposed to METH. These networks
need to be considered when developing medications for the
treatment of METH addicted individuals. Finally, the possible
involvement of these developmental transcription factors in
regulating dopaminergic circuitry in the adult brain exposed to
other dopaminergic toxins need to be evaluated further.
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